Peripheral Arterial Disease (PAD)
Conditions
Brief summary
Major Adverse Kidney Events up to day 90 after intervention (MAKE90)
Detailed description
Main Secondary Endpoint: Post-procedural acute kidney injury (AKI), Major Adverse Kidney Events (MAKE) endpoint up to day 7 (MAKE-7), Single components of MAKE90, Major Adverse Kidney Events at 90 days considering a drop in eGFR by at least 40% (instead of 25% as for the primary endpoint) as compared to baseline, Technical success, Procedural success
Interventions
DRUGSolutrast 370
DRUG370 mg Iod/ml
DRUGInjektionslösung
DRUGOptiray 320 mg Iod/ml Injektionslösung/Infusionslösung
DRUGSolutrast 250
DRUG250 mg Iod/ml
DRUGVISIPAQUETM 270 mg/ml Injektionslösung
DRUGImeron 400
DRUG400 mg Iod/ml
DRUGInfusionslösung
DRUGUltravist®-300
DRUG300 mg Iod/ml
DRUGInjektions- oder Infusionslösung oder Lösung zum Einnehmen
DRUGACCUPAQUE™ 240 Injektionslösung
DRUGACCUPAQUE™ 300 Injektionslösung oder Lösung zum Einnehmen
DRUGImeron 300
DRUGVISIPAQUETM 320 mg/ml Injektionslösung
DRUGImeron 350
DRUG350 mg Iod/ml
DRUGUltravist®-240
DRUG240 mg Iod/ml
DRUGInjektions- oder Infusionslösung
DRUGSolutrast 200
DRUG200 mg Iod/ml
DRUGSolutrast 300
DRUGJopamiro 370 mg J/ml - Stechampullen
DRUGUltravist®-370
Sponsors
Universitaet Leipzig
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major Adverse Kidney Events up to day 90 after intervention (MAKE90) | — |
Secondary
| Measure | Time frame |
|---|---|
| Main Secondary Endpoint: Post-procedural acute kidney injury (AKI), Major Adverse Kidney Events (MAKE) endpoint up to day 7 (MAKE-7), Single components of MAKE90, Major Adverse Kidney Events at 90 days considering a drop in eGFR by at least 40% (instead of 25% as for the primary endpoint) as compared to baseline, Technical success, Procedural success | — |
Countries
Austria, Germany
Outcome results
None listed